Related Experiment Video
Updated: Jan 20, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
Current status of the adjuvant therapy in uterine sarcoma: A literature review
Alessandro Rizzo1, Maria Abbondanza Pantaleo1, Maristella Saponara1
1Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna 40138, Italy.
Abstract:
Uterine sarcomas (US) are rare mesenchymal tumours accounting approximately for 3%-7% of all uterine cancers. Histologically, US are classified into mesenchymal tumours or mixed epithelial and mesenchymal tumours. The group of mesenchymal tumours includes uterine leiomyosarcoma (uLMS, 65% of cases), endometrial stromal sarcoma (ESS, 21%) - traditionally divided into low grade (LG-ESS) and high grade-undifferentiated uterine sarcoma (5%) and other rare subtypes such as alveolar or embryonal rhabdomyosarcoma. Despite the fact that several drugs demonstrated clinical activity in advanced or metastatic settings, the role of postoperative therapy in US remains controversial. In this review, we have summarised the current state of the art, including the chief trials on adjuvant treatment modalities in US, especially focusing on uLMS, LG-ESS and other rare histotypes.
Related Concept Videos
Uterine Tubes
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Marcia's Theory of Identity Status
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Electrical Current

